<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897633</url>
  </required_header>
  <id_info>
    <org_study_id>2019-46</org_study_id>
    <secondary_id>ID-RCB</secondary_id>
    <nct_id>NCT04897633</nct_id>
  </id_info>
  <brief_title>Modulation of Cognitive Control Via Transcranial Continuous Electrical Stimulation of Additional Motor Areas in Parkinson's Patients</brief_title>
  <acronym>STAR-PARK</acronym>
  <official_title>Modulation of Cognitive Control Via Transcranial Continuous Electrical Stimulation of Additional Motor Areas in Parkinson's Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Parkinson's disease (PD), recent work has shown that dopaminergic treatments alter one of&#xD;
      the two aspects of impulsivity: they do not alter the propensity to produce &quot;automatic&quot;&#xD;
      responses, but deteriorate the ability to inhibit and correct (that is, control) them. In&#xD;
      healthy subjects, the investigator's team has also demonstrated that transcranial direct&#xD;
      current &quot;cathodal&quot; electrical stimulation (tDCS) of Supplementary Motor Areas decreases the&#xD;
      frequency of behavioral errors by improving the ability to &quot;correct&quot; responses.&#xD;
&#xD;
      The main objective of this project is to determine whether cathodal tDCS of Supplementary&#xD;
      Motor Areas in PD patients under dopaminergic treatment improves the control and correction&#xD;
      of errors about to be made and compensates for the deficits induced by the treatment.&#xD;
&#xD;
      All participants will perform a reaction time task of choice (Simon's task), with and without&#xD;
      (&quot;sham&quot; session) tDCS. The experimental design of this single-center, single-blind,&#xD;
      randomized study will be that of 3 parallel groups (treated Parkinson's disease, untreated&#xD;
      Parkinson's disease patient, and matched control subjects) with cross-over application of&#xD;
      tDCS. All participants will be blind to the operating mode of the tDCS (either functional or&#xD;
      in &quot;sham&quot; mode corresponding to a control condition). The order of the sessions (with and&#xD;
      without tDCS) will be randomized within each of the 3 groups of subjects. The analysis of&#xD;
      errors about to be made but inhibited in time (known as &quot;early errors&quot;) will be carried out&#xD;
      through electromyographic (surface) recording of muscle activities involved in motor&#xD;
      responses.&#xD;
&#xD;
      tDCS is expected to improve the ability of treated patients to correct their errors about to&#xD;
      be made. This study will thus provide a better understanding of the mechanisms of action&#xD;
      control and possibly propose a new therapeutic approach for treatment-induced impulsivity&#xD;
      disorders in Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rapid error rate.</measure>
    <time_frame>Day 2</time_frame>
    <description>Responses recorded on the opposite side to that expected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid error rate.</measure>
    <time_frame>Day 3</time_frame>
    <description>Responses recorded on the opposite side to that expected</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Patients ON</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will performed Simon's task with tDCS active or sham when treatment is OFF (for standard care procedure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients OFF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will performed Simon's task with tDCS active or sham when treatment is ON (for standard care procedure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will performed Simon's task with tDCS active or sham</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial electric stimulation</intervention_name>
    <description>Simon's task assessment when under tDCS</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients OFF</arm_group_label>
    <arm_group_label>Patients ON</arm_group_label>
    <other_name>DC STIMULATOR PLUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Parkinsonien patients:&#xD;
&#xD;
          -  Age&gt; 18 years old&#xD;
&#xD;
          -  Idiopathic Parkinson's disease meeting the diagnostic criteria as defined by Ward and&#xD;
             Gibb (1990)&#xD;
&#xD;
          -  Patients usually taking dopaminergic treatment.&#xD;
&#xD;
          -  No cognitive deterioration with: a Montreal Cognitive Assessment (MoCA) score ≥ 26&#xD;
&#xD;
          -  Patient with Parkinson's disease in the advanced motor complications stage for which&#xD;
             surgical treatment is being considered&#xD;
&#xD;
        Inclusion Criteria for healthy subjects&#xD;
&#xD;
          -  Age&gt; = 18 years old&#xD;
&#xD;
          -  Patient free from Idiopathic Parkinson's Disease&#xD;
&#xD;
          -  No cognitive deterioration: MMSE (MiniMentalSate Evaluation)&gt; 26&#xD;
&#xD;
        Exclusion Criteria for both parkinsonien patients an healthy volunteers:&#xD;
&#xD;
          -  Uncorrected altered visual acuity&#xD;
&#xD;
          -  Dyschromatopsia (especially color blindness)&#xD;
&#xD;
          -  Psychotropic treatment introduced or modified recently (&lt;1 month)&#xD;
&#xD;
          -  Wearing a pacemaker (Pace Maker or Implantable Defibrillator)&#xD;
&#xD;
          -  Pregnancy (verified by a urine pregnancy test for women of childbearing age)&#xD;
&#xD;
          -  Other central nervous system disease (other parkinsonian syndrome, epilesia, stroke,&#xD;
             etc.) or peripheral&#xD;
&#xD;
          -  Intracranial metal implants on the cephalic stage and cochlear implant&#xD;
&#xD;
          -  Untreated progressive mood or psycho-behavioral disorder&#xD;
&#xD;
          -  Severe and poorly controlled eczema&#xD;
&#xD;
        Exclusion criteria for Parkinson's patients only:&#xD;
&#xD;
          -  Significant and disabling abnormal movement, not allowing good acquisition of the EMG&#xD;
             signal (tremors or dyskinesias)&#xD;
&#xD;
          -  Wearer of a Deep Brain Stimulation device (CI at tDCS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>APHM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederique Fluchere, MD</last_name>
    <phone>0491389368</phone>
    <phone_ext>33</phone_ext>
    <email>frederique.fluchere@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service Neurologie et pathologies du mouvement</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Fluchère</last_name>
      <email>frederique.fluchere@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transcranial stimulation</keyword>
  <keyword>tDCS</keyword>
  <keyword>simon task</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

